I am sorry for the delay in contacting you with the referee reports. We have now received a complete set of reviews from the referees, which I include below for your information. As you will see, although all referees appreciate the interest of the topic and referee 2 is supportive of the study, referees 1 and 3 feel it is inconclusive at this stage and raise numerous concerns, although providing also ways in which to address them.
Before making a final decision on your study, and as some of the suggested experiments are rather time consuming, I would would like to ask what you would be able to do within a 3 month period to address the referee concerns. To ensure that the decision-making process is not delayed, please respond within 24-48 hours.
I look forward to your response.
REFEREE REPORTS:
Referee #1
The manuscript by Heilbronner et al. describes the potential discovery that different Aβ aggregate morphotypes can be transmitted to recipient mice upon intracerebral inoculation. This phenomenon is reminiscent of the strain concept in prion diseases, which posits that disease phenotypes result from different conformations of the disease-associated prion protein isoform (PrPSc). Discrimination of the different morphotypes/strains is carried out by pathology, measurement of ratios between Aβ isoforms and staining with conformation-dependent, luminescent-conjugated polythiopene (LCP). The present study aimed to show that different strains of Aβ are formed in two transgenic mouse models and stably propagated <i>in vivo</i>. In my opinion, the data presented here does not clearly prove the observed differences in morphology and transmissible strains.
The novel aspect of the data presented in Figure 1 is that amyloid aggregates from different Tg mouse models stain differently with the chosen LCP dye. It further describes the different Aβ amyloid characteristics present in the two chosen transgenic mouse models (e.g., differences in morphology and Aβ isoform ratios). While the Aβ isoform ratios seem to be a relatively consistent marker, I am concerned about the LCP measurements. In a related study coauthored by the same group, Nystrom et al. (2013) show that changes in fluorescence of LCPs bound to Aβ aggregates can be also found within a given transgenic mouse model upon aging. Does this mean that Aβ "morphotypes" can change within one transgenic mouse model over time? This finding is referenced in the current manuscript but would represent an important point for the interpretation of the current data. From this, it is not clear if the basis for the change in fluorescence spectra is a conformational change, change in plaque density or inclusion of non-Aβ proteins into aggregates during aging (or a combination thereof.) It is important for the current study to let APPPS1 mice age further and measure the fluorescence spectra obtained from plaques in an ~18-month-old APPPS1 mouse. In case of changing fluorescence spectra, the strain characteristics measured by LCP would be very dynamic and a function of the age of the animal (or the individual aggregate) and therefore LCPs might not represent the best tool to differentiate strains in mouse models of Aβ amyloidosis. It would also be nice to show that the differences in LCP fluorescence also persist when the aggregates are purified and to compare the fluorescence of LCPs measured "<i>ex situ</i>" in bulk (instead of individual plaque measurements) with the <i>in situ</i> measurements.
Brain samples from each transgenic mouse model were inoculated into younger recipient mice of these two lines. The pathological findings of these experiments were further identified by immunohistochemistry and staining of the amyloid plaques by LCPs. Results of these measurements are presented in Figure 2A -E, but were essentially already published in the paper by MeyerLuehmann et al. (Science, 2006;  Figure 2 ) in a more detailed form (overviews of the hippocampal area from each experiment instead of just one "representative" image). The results of Figure 2F -I are represented in the quantification in Figure 3 . This figure would have been a good place to discuss the histopathological distribution of Aβ plaques in more detail and if it can be a characteristic preserved across different transmission experiments as found with PrPSc strains. The authors only show in their inoculation experiments that the pathological distribution of Aβ plaques is changing even in the initial APPPS1->APPPS1 transmissions (little Aβ staining in hippocampus/CA1 in Figure1B and strong staining in the area in Figure 2A ). This might represent an inoculation artifact or show that strain characteristics are not fully developed in aged, uninoculated Tg mice, and progress only upon transmission. Therefore, I suggest that further serial passaging needs to be performed (and maybe different sites of inoculation) to identify the stable strain features upon transmission experiments.
In Figure 3 , the authors analyze the results from the transmission experiments in regard to the Aβ isoform ratio and the outcome of the fluorescence microscopy with the LCP. In contrast to Figure 3 , Aβ isoform ratio measurements in Figure 1 represent ratios of total brain Aβ, while the ratios in Figure 3 are obtained through laser dissection of individual plaques. It would be very useful to display both measurements (total Aβ ratios and laser dissected Aβ ratios), since the plaque selection could have been biased towards a certain type (size and morphology) of plaque.
Animals used for the inoculation experiments were at very different ages when inoculated (APP23: 4-6 months; APPPS1: 2-3 months), creating an uneven starting point for these experiments. Therefore, it is not surprising that the authors could not establish a significant difference for the Aβ isoform ratios in the inoculation experiments performed in APPPS1 mice. APPPS1 mice show aggregated Aβ as early as 6 weeks of age (Radde et al. 2006) . As discussed by the authors, spontaneously formed aggregates are already present and might act as the dominating seed. In this scenario, inoculation with different aggregates might only have limited contribution to the aggregate composition and morphology. These factors question the reliability of the findings in APPPS1 mice in Figures 2 and 3 . Using younger mice of uniform age (rather than an age range, as specified) might provide a better approach; alternatively, the authors may consider using mouse models with slower amyloid accumulation. More important, this observation also reveals that the two measures applied to characterize the morphotypes/strains can be disconnected from each other. For example, upon transmission of APP23->APPPS1, the LCP staining experiments detected the 534/631-nm ratio reminiscent of the APP23 "strain," whereas the Aβ ratios were more similar to APPPS1->APPPS1 transmissions or to the spontaneous aggregation of Aβ in APPPS1 mice. Again, this observation questions the chosen methods for identification and differentiation of Aβ strains by LCP. This clear disconnection is not mentioned in the manuscript at all and warrants discussion in greater detail.
The finding that Aβ isoform ratios can be preserved through transmission experiments represents a very interesting point for further studies. The authors should discuss a possible mechanism and compare it to findings of other groups. For example, Stohr et al. (2012) found that the inoculation of synthetic Aβ(1-40) induces the aggregation of both Aβ isoforms and did not show a preference for Aβ(1-40), which seems to be a contradiction to the findings presented in the current manuscript.
I am convinced that the outlined approach in general might lead to the discovery of different morphotypes/strains of Aβ amyloids in future studies, but the manuscript in its current form falls short in demonstrating that the Aβ amyloids obtained from different mouse models are true strains. Therefore, I do not recommend publishing this manuscript in <i>EMBO Reports</i> without major revisions, such as new biochemical/pathological experiments and additional transmission studies.
Referee #2
In the current manuscript, Heilbronner and co-authors show a strain-like transmission of amyloidosis in two mouse models, APP23 and APP/PS1. Both models overexpress APP Swedish but generate plaques of different morphology, which can be explained by different Abeta42/40 ratios in the mice. Intracerebral injection of APP23 mouse with a brain extract from an aged APP/PS1 mouse resulted in formation of plaques conformationally reminiscent of deposits found in APP/PS1 mouse. Conversely, an APP23 mouse brain extract injected in APP/PS1 host did not result in APP23-alike pattern of amyloidosis in host mice, probably due to the higher content of aggregation-prone Abeta42 in the host brain. This finding illustrates different seeding efficiency of Abeta mixtures that is (similarly to the toxic efficiency shown by other groups) dependent on Abeta42. Did the authors try to mimic the strain-like transmission by injecting the mice with defined synthetic mixes of Abeta40/42? LCP dye used in the current study seems to be pretty sensitive to Abeta ratio in plaques (Fig.1) . It would be interesting to see whether the 10x decrease in Abeta40 is sufficient to cause red shift in LCP fluorescence of Abeta 40/42 model mixture, or whether there are other yet undefined factors that contribute to conformational (spectral) heterogeneity of amyloid plaques.
Referee #3
The manuscript "Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice" by Helibronner et al. focuses on the existence of different Aβ morphotypes observed in AD patients and the available mouse models and their resultant seeding and propagation in a given host. The same group has published a landmark paper showing that amyloid pathology can be induced in young transgenic mice by the intracerebral injection of amyloid containing brain extracts from either AD tissue or transgenic mice (Meyer-Luehmann, Science 2006 ) . In this previous work the authors have shown the contribution of both the donor and host to the resultant amyloid propagation in the host brain. Although these previous finding were very exciting the current work does little to build on this finding. In fact, there is very little that is novel. The use of tPTAA to qualitatively identify the amyloid aggregate conformations is interesting, but the correlation between the Abeta 40:42 ratio is nothing more than correlative, and the use of these dyes to distinguish "morphotypes" of amyloids is also not novel. The enthusiasm for this approach is also diminished when considers the obvious difference between dense core and diffuse plaques. In summary, while the concept of seeded amyloids is considered topical and exciting, this manuscript does little to add to our understanding of the field. Several minor points are also noted: Figure 1 : The brain section provided at low magnification to appreciate the different pathology of the two strains and are double stained with congo red and Aβ antibody. First , it is very hard to notice the congo red staining in both the low and high magnification images. Second, the APPPS1 plaques are referred as compact by the congo red "red" staining. Congo red will bind cytoplasm and any proteinous aggregate and to evaluate the amyloid compact features one should use polarized light and consider the green birefringence as indicative of amyloid.
Figure 2: -The authors quantify the amyloid burden as either total Aβ immunoreactivity or compact amyloid. It is not specified anywhere in the text (results, legends or methods) how the compact plaques where analyzed (Th-S, just morphology?). Also, the methods suggested names of two Aβ antibodies for IHC that binds Aβ40 . This is probably a mistake and one is for Aβ42. In any case, it should be specified which one was used for the total amyloid burden calculation. This is quite important information as the presence of either Aβ40 or Aβ42 will dictate the resultant conformation of the plaque. The best way to go for this kind of analysis is with a pan-Aβ antibody for either N terminus or mid region.
-As the APP23 and APPPS1 plaques are very different in size, it would be better to look at the plaque size and numbers as an outcome not just the area these plaques occupy. This would be much more useful in appreciating the contribution of the exogenous Aβ to the resultant pathology in the host. It stated that the APP23 pathology after APP23 extract inj. is 2-fold higher compared to the APP23 after injection with APPPS1 extract, again this could be the same number of plaques with double the area they occupy. This is further supported by the fact that there is no difference in the compact plaques comparison.
-Regarding the experiments with the APPPS1 hosts: as these mice develop the pathology quite early and have a substantial pathology at the age of sacrifice , it will be useful to provide images and quantification of the naïve / Saline injected APPPS1 to appreciate the contribution of exogenous amyloid to the outcome pathology. Figure 3 : -Regarding the effect of the seeding on Aβ40/42 ratio: the composition of these 40 and 42-amino acid peptides in the ISF of these transgenic mice is dictated by the mutation they carry. While the APP23 have increased β-cleavage which does not affect the γ-cleavage and favors Aβ40 production, the PS1 mutation affects the γ-cleavage and favors Aβ42. It is not perceivable that exogenous administration of different amyloid morphotypes will affect this composition which is upstream to the aggregation process. The changes observed in APP23 injected with APPPS1 could reflect the composition of the highly concentrated donor aggregates compared to the donor Aβ levels at this stage. It could be that this is not true for the APPPS1 mice as their endogenous Aβ levels are higher and already have some deposition at this age. I would be useful to provide the control they have previously done for the seeding by sacrificing the mice a week after injection. If the results indeed reflect the donor Aβ40/42 composition it should be less pronounced long before the pathology has propagated. --The authors suggest that the different aggregates can recruit Aβ40 or 42 to a different extent which may be the way they affect the ratio. If this is the case a good control is to do it in a wild type mouse which we know does not develop any pathology, meaning these amyloids do not recruit the murine Aβ. In this case the ratio should not be altered by the amyloid injection.
Statistics:
In the methods, there is no mention of the statistical analysis done. It is described in the text but with very little details. For figure 1, its stated in the legends that a t-test was done. Is it a parametric / non-parametric? Probably considering the size sample these should be non parametric For figure 2, there is no statistic analysis mentioned that can support the comparisons made in the text. Methods: It is mentioned both in the results and the methods that the APP23 mice were used at 4-6 months of age and sacrificed 3 months after. For the reciprocal experiment with the APPPS1 as the host, mice were used at 1.5-3 months of age and analyzed 1.5-3 months later. This is a very large spread in duration for this aggressive amyloid depositor.
Correspondence -authors 26 April 2013
Thank you very much for the detailed reviews.
Referee 1 says in the end....the manuscript falls short in demonstrating that the Abeta amyloids obtained from the different mouse models are true "strains".
I agree and if we could show "true strains" I am fairly positive NATURE and SCIENCE would publish our work.
To show "true strains" (in vivo) we would have to generate tools that the prion community has generated over many years. For the Abeta community this would mean to generate tg mouse lines that express and deposit either only Abeta40 or only Abeta42 on a murine APP ko background. With such models then second (serial) transmission experiments would have to be done. (To do serial transmission with the APP23 and APPPS1 models does not make sense because of the endogenous confounding murine Abeta species among other problems). Such experiments are not feasible and may take 1-2 years. However as we state in our manuscript, our results are "reminiscent of strains" or "strain-like" (we never say strain).
We have done what is feasible with the current techniques/model systems and we thought EMBO Reports is the appropriate journal for such exciting results on which we and many other hopefully will build in the future.
saying this 1. yes, I believe we could address the points of all three referees within 3 months, however 2. It is impossible to do the suggested serial passage experiment or do the seeding in another mouse line as suggested as by refeee 2. Moreover, 3. referee 3 says "...while the topic is interesting this manuscript does not add to our understanding of the field". I naturally disagree because we are the first to go beyond the pure morphological description of "strain-like" transmission of Abeta aggregates/morphotypes/lesions. I am not aware that anybody has shown this. I am aware that a paper will be in PNAS in which Tau extracts from different human diseases have been injected in Tau transgenic mice. Then second transmission has in fact been done but the analysis of the Tau lesions is purely morphological in a way similar to what we have done in our work Meyer-Lühmann et al., Science 2006. Our work submitted to EMBO reports goes well beyond a simple morphological description! However, I am afraid referee 3 has another opinion. Although I believe that we can address his concern, I am afraid he/she will not change his/her view.
Thus, if you as the editor give us the chance to address all the issues without asking for the serial transmission/another mouse line (point 2 above), I believe we could address all the remaining issues. However, I am afraid referee 3 will insist on his/her negative opinion and this would need an editorial decision. Many thanks for your detailed response. I do consider -as do referees 1 and 2-that the study would sufficiently advance the field if the referee concerns can be adequately addressed and the study thus strengthened. In this regard, we would not consider the novelty issues brought up by referee three as precluding publication here.
It is good to hear you feel able to address all referee concerns in full except the transmission studies suggested by referee 1 or use of another mouse line. As I understand, this would include addressing the concern raised by referees 1 and 3 regarding the discrepancy between the age of inoculation of the two mouse models, and analyzing aged APPPS1 mice. This would be a sufficient revision in principle for publication in EMBO reports and we would not insist on the transmission studies. Nevertheless, please note that it is EMBO reports policy to undergo one round of revision only and thus, acceptance of your study will depend on how well the other issues are addressed and the outcome of the next, final round of peer-review.
Revised manuscripts must be submitted within three months of a request for revision unless previously discussed with the editor; they will otherwise be treated as new submissions. Revised manuscript length must be a maximum of 28,500 characters (including spaces). When submitting your revised manuscript, please also include editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referees.
We also welcome the submission of cover suggestions or motifs that might be used by our Graphics Illustrator in designing a cover.
I look forward to seeing a revised form of your manuscript when it is ready. In the meantime, do not hesitate to get in touch with me if I can be of any assistance.
1st Revision -authors' response 18 July 2013
Reviewer #1 : Comment 1 (first) and 9 (last comment): The present study aimed to show that different strains of Aβ are formed in two transgenic mouse models and stably propagated in vivo. In my opinion, the data presented here does not clearly prove the observed differences in morphology and transmissible strains.... I am convinced that the outlined approach in general might lead to the discovery of different morphotypes/strains of Aβ amyloids in future studies, but the manuscript in its current form falls short in demonstrating that the Aβ amyloids obtained from different mouse models are true strains.
Response 1: We refer in our paper to "seeded strain--like transmission of Aβ--amyloid morphotypes". We purposely avoided the term " Aβ strains" because we think that it is premature to refer to "Aβ strains" in the sense of prion strains (Aguzzi, Nature Neuroscience 2008). We do, however, believe that our data hint to transmissible Aβ morphotypes. --To show "true Aβ strains" (in vivo) we would have to generate tools that the prion community has generated over many years. For the Aβ community this would mean to generate tg mouse lines that express and deposit (!) either only Aβ40 or only Aβ42 on a murine APP ko background. With such models second (serial) transmission experiments would then have to be done. (Serial transmissions with the APP23 and APPPS1 models do not really make sense because of the endogenous confounding murine Aβ species and the aggressive PS1 mutation of the APPPS1 mouse model). In the present study we have done what is feasible for us at the moment with the current techniques/model systems and we thought EMBO Reports is the appropriate journal for such exciting results on which we and many other will hopefully build in the future. Comment 2: I am concerned about the LCP measurements. In a related study coauthored by the same group, Nystrom et al. (2013) show that changes in fluorescence of LCPs bound to Aβ aggregates can be also found within a given transgenic mouse model upon aging. Does this mean that Aβ "morphotypes" can change within one transgenic mouse model over time? This finding is referenced in the current manuscript but would represent an important point for the interpretation of the current data. From this, it is not clear if the basis for the change in fluorescence spectra is a conformational change, change in plaque density or inclusion of non--Aβ proteins into aggregates during aging (or a combination thereof.) It is important for the current study to let APPPS1 mice age further and measure the fluorescence spectra obtained from plaques in an 18--month--old APPPS1 mouse. In case of changing fluorescence spectra, the strain characteristics measured by LCP would be very dynamic and a function of the age of the animal (or the individual aggregate) and therefore LCPs might not represent the best tool to differentiate strains in mouse models of Aβ amyloidosis. It would also be nice to show that the differences in LCP fluorescence also persist when the aggregates are purified and to compare the fluorescence of LCPs measured "ex situ" in bulk (instead of individual plaque measurements) with the in situ measurements.
Response 2: We would like to point out that the age--related changes in LCP fluorescence of individual Aβ plaques in Nystrom et al. 2013 was not distinguished by changes in fluorescence from a single LCP. The phenomenon was only revealed by using two distinct LCPs. Nevertheless, to address this referee´s concern we have included t--PTAA staining of APPPS1 plaques in 6--vs.18--month--old mice and have calculated the ratio of 534nm/631nm. We did not find a difference between the 6 month--old APPPS1 mice and the 18--month--old APPPS1 mice and have added these data as supplementary Figure S1 in the manuscript. --We also have now purified β--amyloid from a 28--month--old APP23 mouse and 20--month--old APPPS1 mouse and have done t--PTAA staining with subsequent spectral analysis. Results are not as clear as in the tissue sections but overall the observations were similar to what we observe in the intact plaques. We have now added these results as supplementary Figure S2 to the revised manuscript. We now refer to these new results in the result part on page 4 bottom/page 5 top. We also added two corresponding paragraphs to the method section (page 10 and 13) in which we describe the preparation of the amyloid fibrils and the collection of the emission spectra from the fibrils. Comment 3: Brain samples from each transgenic mouse model were inoculated into younger recipient mice of these two lines. The pathological findings of these experiments were further identified by immunohistochemistry and staining of the amyloid plaques by LCPs. Results of these measurements are presented in Figure  2A --E, but were essentially already published in the paper by Meyer--Luehmann et al. we decided not to show again the entire hippocampus in this manuscript but focus on the differential staining in the molecular layer of the dentate gyrus. We describe the characteristics of the induced Aβ deposits for each of the four groups in the result part on page 5 and in Figure legend 2. Please note that we added mice to the panel D and E (Fig. 2 ), see response 6 to this referee. Comment 4. The authors only show in their inoculation experiments that the pathological distribution of Aβ plaques is changing even in the initial APPPS1-->APPPS1 transmissions (little Aβ staining in hippocampus/CA1 in Figure1B and strong staining in the area in Figure 2A ). This might represent an inoculation artifact or show that strain characteristics are not fully developed in aged, uninoculated Tg mice, and progress only upon transmission. Therefore, I suggest that further serial passaging needs to be performed (and maybe different sites of inoculation) to identify the stable strain features upon transmission experiments.
Response 4: Indeed the pattern in the dentate gyrus is to some extent the result of the injection (see also Eisele et al., PNAS 2009 for the pattern of the induced amyloid vs endogenous amyloid in various brain regions). However, we would not refer to it as an artifact. Our transgenic mice as well as our inoculation paradigm are experimental setups aiming to deciphering specific aspects of the pathomechanims of the disease and do not necessarily have to mirror the true in vivo conditions. We agree with this referee that serial passaging is definitely the obvious direction to go, we believe, however, that this is beyond the scope of the present manuscript. See also the more general comment 1 to this referee. Comment 5: In Figure 3 , the authors analyze the results from the transmission experiments in regard to the Aβ isoform ratio and the outcome of the fluorescence microscopy with the LCP. In contrast to Figure 3 , Aβ isoform ratio measurements in Figure 1 represent ratios of total brain Aβ, while the ratios in Figure 3 are obtained through laser dissection of individual plaques. It would be very useful to display both measurements (total Aβ ratios and laser dissected Aβ ratios), since the plaque selection could have been biased towards a certain type (size and morphology) of plaque.
Response 5:
We have now included the laser--dissected Aβ ratios to figure 1J . Naturally we have also updated Figure legend 1. Comment 6: Animals used for the inoculation experiments were at very different ages when inoculated (APP23: 4--6 months; APPPS1: 2--3 months), creating an uneven starting point for these experiments. Therefore, it is not surprising that the authors could not establish a significant difference for the Aβ isoform ratios in the inoculation experiments performed in APPPS1 mice. APPPS1 mice show aggregated Aβ as early as 6 weeks of age (Radde et al. 2006) . As discussed by the authors, spontaneously formed aggregates are already present and might act as the dominating seed. In this scenario, inoculation with different aggregates might only have limited contribution to the aggregate composition and morphology. These factors question the reliability of the findings in APPPS1 mice in Figures 2 and 3 . Using younger mice of uniform age (rather than an age range, as specified) might provide a better approach; alternatively, the authors may consider using mouse models with slower amyloid accumulation.
Response 6: We have inoculated APPPS1 mice at 1.5 --2 months of age with an inoculation time of 1.5 --2 months (group 1). A second group was inoculated at 3 months of age with inoculation time of 3 months (group 2). Based on the morphological criteria as described in Figure 2 we have not seen qualitative differences between the mice and thus we picked the extremes (1,5 mo old mice with a 1,5 mo incubation period and 3 mo old mice with a 3 mo incubatiuon period) for the analysis. In response to the question of this referee we have now added all the mice to the analysis of Fig. 2 (n=8) , have updated the corresponding figure legend and say in the text (result part) that we did not see a qualitative difference and thus included the extremes in the in--depth--analysis presented in Figure 3 . The uneven starting point in the APP23 model appears less of a concern (see Hamaguchi et al., Acta Neuropathology 2012). Nevertheless, we agree with this referee and state in the discussion that the spontaneous endogenous nucleation events in the APPPS1 mouse may have obscured the seeded nucleation. Comment 7: More important, this observation also reveals that the two measures applied to characterize the morphotypes/strains can be disconnected from each other. For example, upon transmission of APP23-->APPPS1, the LCP staining experiments detected the 534/631--nm ratio reminiscent of the APP23 "strain," whereas the Aβ ratios were more similar to APPPS1-->APPPS1 transmissions or to the spontaneous aggregation of Aβ in APPPS1 mice. Again, this observation questions the chosen methods for identification and differentiation of Aβ strains by LCP. This clear disconnection is not mentioned in the manuscript at all and warrants discussion in greater detail.
Response 7: We see the LCPs as one (of many) tools to characterize/analyse Aβ morphotypes. It is still not clear how LCPs bind to amyloids and thus, we believe it is premature to conclude that Fig. 3B points to a "disconnection". A simple floor effect may underly the "disconnection". Unfortunately, there are space limitations that do not allow us to discuss this in the discussion part. Moreover, albeit very interesting, we feel that such a discussion will not add to or change the key conclusion of the paper.
Comment 8:
The finding that Aβ isoform ratios can be preserved through transmission experiments represents a very interesting point for further studies. The authors should discuss a possible mechanism and compare it to findings of other groups. For example, Stohr et al. (2012) found that the inoculation of synthetic Aβ(1--40) induces the aggregation of both Aβ isoforms and did not show a preference for Aβ(1--40), which seems to be a contradiction to the findings presented in the current manuscript.
Response 8: We do not know the mechanism and do not feel comfortable to speculate beyond what we write in the discussion namely that our results imply the existence of a selection mechanism, whereby the seeded Aβ deposits incorporate the host--generated Aβ isoform that resembles the composition of the seed. One may argue that the amyloid spine of Aβ42 fibrils is different from an Aβ40 amyloid spine and that homotypic seeding is more likely than cross--seeding (see Eisenberg and Jucker, Cell, 2012) . However, these are mainly speculations and no precise structural informations are available from brain--derived Aβ fibrils. Last but not least, we believe EMBO report is not the format to discuss and speculate about findings in length. The increase in Aβ42 and Aβ40 in Stöhr et al is interesting. However, please note that synthetic Aβ is at least 100 less efficient to induce cerebral amyloidosis compared to brain--derived material -most likely because synthetic fibrils have a conformation that is different from Aβ fibrils in brain or lack co--factors that are instrumental for the seeding (see also Paravastu et al., PNAS, 2009) . Please see also comment 1 to referee 2 below. Moreover, Stöhr et al analysed the entire brain (mixing CAA and parenchymal amyloid and collapsing brain regions). activity, however, in 100x higher concentrations compared to the brain--derived Aβ--containing material and they used incubations times of 8 months. Unfortunately, we cannot extend the incubation time in the APP23 and APPPS1 mouse models because endogenous amyloid disposition will occur (to a significant degree even in the hippocampus) and make the interpretation of the induced amyloid difficult. In future studies injection in another host may be an interesting option. However, synthetic Aβ fibrils are clearly different from brain--derived Aβ fibrils either in conformation of co--factors (see also Response 8 to referee 1). Comment 2: LCP dye used in the current study seems to be pretty sensitive to Abeta ratio in plaques (Fig.1) . It would be interesting to see whether the 10x decrease in Abeta40 is sufficient to cause red shift in LCP fluorescence of Abeta 40/42 model mixture, or whether there are other yet undefined factors that contribute to conformational (spectral) heterogeneity of amyloid plaques.
Response 2: We have tried to mimic the tPTAA spectral profiling observed in brain slices and fibrils prepared from brain using recombinant Aβ40 and Aβ42. In this respect we have so far been unable to mimic this behavior in vitro. Reviewer #3: Comment 1: In fact, there is very little that is novel. The use of tPTAA to qualitatively identify the amyloid aggregate conformations is interesting, but the correlation between the Abeta 40:42 ratio is nothing more than correlative, and the use of these dyes to distinguish "morphotypes" of amyloids is also not novel. The enthusiasm for this approach is also diminished when considers the obvious difference between dense core and diffuse plaques. In summary, while the concept of seeded amyloids is considered topical and exciting, this manuscript does little to add to our understanding of the field. , it is only in the present manuscript that we provide (quantitative) evidence (although to some extent of correlative nature) that the various morphotypes reflect variations in the molecular composition and/or conformation of the aggregated Aβ in the (donor) brain extracts. We feel that these results are exciting and the nucleus for hopefully many studies to come. Comment 2: Figure 1 :The brain section provided at low magnification to appreciate the different pathology of the two strains and are double stained with congo red and Aβ antibody. First , it is very hard to notice the congo red staining in both the low and high magnification images. Second, the APPPS1 plaques are referred as compact by the congo red "red" staining. Congo red will bind cytoplasm and any proteinous aggregate and to evaluate the amyloid compact features one should use polarized light and consider the green birefringence as indicative of amyloid.
Response 2: We have replaced Figure 1C and 1D with green--yellow birefringence. The observation that plaques in the APPPS1 mouse brain are predominately compact and congophil is also reported in Radde et al., EMBO Rep 2006 . Comment 3: Figure 2 : --The authors quantify the amyloid burden as either total Aβ immunoreactivity or compact amyloid. It is not specified anywhere in the text (results, legends or methods) how the compact plaques where analyzed (Th--S, just morphology?). Also, the methods suggested names of two Aβ antibodies for IHC that binds Aβ40 . This is probably a mistake and one is for Aβ42. In any case, it should be specified which one was used for the total amyloid burden calculation. This is quite important information as the presence of either Aβ40 or Aβ42 will dictate the resultant conformation of the plaque. The best way to go for this kind of analysis is with a pan--Aβ antibody for either N terminus or mid region.
Response 3: We have used combined staining for Congo red and Aβ (immunohistochemistry) to quantify total Aβ load and congophilic amyloid load as in many previous papers from our laboratory (for a more recent one see Maia et al., Science Translation Medicine, 2013) . However, the induced amyloid in the subgranular layer was so dense that the Aβ immunoreactivity masks in most cases the Congo red staining. Thus, we felt that it is not appropriate to call it congophilic plaques but refered to compact plaques instead. We have now clarified this in the method section. --Both Aβ antibodies used were raised against fibrillary Aβ1--40. The difference between NT12 and CN3 is just that it is another rabbit. Both (polyclonal) antibodies recognize Aβ40 and Aβ42. We distinguish the two Aβ species with our urea--based gel system that, in opinion, is more reliable compared to Aβ40--vs. Aβ42--specific antibodies. We have rephrased the method part to make this clear and thank the referee for bring this confusion to our attention. Comment 4:--As the APP23 and APPPS1 plaques are very different in size, it would be better to look at the plaque size and numbers as an outcome not just the area these plaques occupy. This would be much more useful in appreciating the contribution of the exogenous Aβ to the resultant pathology in the host. It stated that the APP23 pathology after APP23 extract inj. is 2--fold higher compared to the APP23 after injection with APPPS1 extract, again this could be the same number of plaques with double the area they occupy. This is further supported by the fact that there is no difference in the compact plaques comparison.
Response 4: We agree with this referee and appreciate his/her thoughts. The problem of such an analysis is that the induced amyloid in the subranular cell layer is so dense that it is virtually impossible to distinguish individual plaques for quantitative analysis. The induced amyloid in the molecular layer is mostly diffuse and do not fit into a "plaque" schema. Finally, assuming that we confirm the speculation of the referee and find the same number of plaques with double the area they occupy, we feel that this would not change or challenge our findings and conclusions, namely that the different morphotypes are induced. Comment 5: Regarding the experiments with the APPPS1 hosts: as these mice develop the pathology quite early and have a substantial pathology at the age of sacrifice , it will be useful to provide images and quantification of the naïve / saline injected APPPS1 to appreciate the contribution of exogenous amyloid to the outcome pathology. Fig. 3B ). Thus, we feel that it is not necessary to show such a figure again. However, we do now refer to the two papers in the figure legend 2. Comment 6: Figure 3 :--Regarding the effect of the seeding on Aβ40/42 ratio: the composition of these 40 and 42--amino acid peptides in the ISF of these transgenic mice is dictated by the mutation they carry. While the APP23 have increased β--cleavage which does not affect the γ--cleavage and favors Aβ40 production, the PS1 mutation affects the γ--cleavage and favors Aβ42. It is not perceivable that exogenous administration of different amyloid morphotypes will affect this composition which is upstream to the aggregation process. The changes observed in APP23 injected with APPPS1 could reflect the composition of the highly concentrated donor aggregates compared to the donor Aβ levels at this stage. It could be that this is not true for the APPPS1 mice as their endogenous Aβ levels are higher and already have some deposition at this age. I would be useful to provide the control they have previously done for the seeding by sacrificing the mice a week after injection. If the results indeed reflect the donor Aβ40/42 composition it should be less pronounced long before the pathology has propagated. figure 1 , its stated in the legends that a t--test was done. Is it a parametric / non--parametric? Probably considering the size sample these should be non parametric. For figure 2, there is no statistic analysis mentioned that can support the comparisons made in the text.
Response 8: We believe that t--tests are always parametric and are not aware of non--parametric t--tests. We have looked at the data and as they are normally distributed we chose a parametric test. In respect to the concerns raised by this referee we additionally calculated a (non--parametric) Mann--Whitney U test (LCP measures: Mann--Whitney U=0.0, n(APP23=5; n(APPPS1)=6; P<0.01 two--tailed; Aβ40/42 ratio: Mann--Whitney U=0.0, n(APP23=5; n(APPPS1)=6; P<0.01 two--tailed). We have added the missing statistic analysis to figure 2 and are very grateful to this referee to point out this failure of adding these statistical numbers to figure 2. Comment 9: Methods: It is mentioned both in the results and the methods that the APP23 mice were used at 4--6 months of age and sacrificed 3 months after. For the reciprocal experiment with the APPPS1 as the host, mice were used at 1.5--3 months of age and analyzed 1.5--3 months later. This is a very large spread in duration for this aggressive amyloid depositor.
Response 9: See response 6 to referee 1. Thank you for your patience while we have reviewed your revised manuscript. The revised version has been seen by referee 1. As you will see from the report at the end of this email, s/he believes the revision has sufficiently addressed the issues raised and supports publication in EMBO reports.
I am therefore writing with an 'accept in principle' decision, which means that I will be happy to accept your manuscript for publication once the text has been shortened appropriately. Shortening may be made easier by combining the Results and Discussion into a single section, which we require, and which will help eliminate the redundancy that is inevitable when discussing the same experiments twice. Also, please note that basic Materials and Methods required for understanding the experiments performed must remain in the main text, but additional detailed information may be included as Supplementary Material.
As a standard procedure, we edit the title and abstract of manuscripts to make them more accessible to a general readership. Please find the edited version of the abstract (I have not modified the title) below my signature and let me know if you do NOT agree with any of the changes.
We now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please contact me.
After all remaining corrections have been attended to, you will receive an official decision letter from the journal accepting your manuscript for publication in the next available issue of EMBO reports. This letter will also include details of the further steps you need to take for the prompt inclusion of your manuscript in our next available issue.
Thank you for your contribution to EMBO reports. ******************* Edited abstract
The polymorphic lesions present in individuals with Alzheimer´s disease are collectively known as cerebral β-amyloidosis. Amyloid precursor protein (APP) transgenic mouse models similarly develop β-amyloid depositions that differ in morphology, binding of amyloid conformation-sensitive dyes, and Aβ40/Aβ42 peptide ratio. To determine the nature of such β-amyloid morphotypes, β-amyloid-containing brain extracts from either aged APP23 brains or aged APPPS1 brains were intracerebrally injected into the hippocampus of young APP23 or APPPS1 transgenic mice. APPPS1 brain extract injected into young APP23 mice induced β-amyloid deposition with the morphological, conformational, and Aβ40/Aβ42 ratio characteristics of β-amyloid deposits in aged APPPS1 mice, whereas APP23 brain extract injected in young APP23 mice induced β-amyloid deposits with the characteristics of β-amyloid deposits in aged APP23 mice. Injecting the two extracts into the APPPS1 host revealed a similar difference between the induced β-amyloid deposits, although less prominent, and the induced deposits were similar to the β-amyloid deposits found in aged APPPS1 hosts. These results suggest that the molecular composition and conformation of aggregated Aβ in APP transgenic mice can be maintained by seeded conversion. ******************* REFEREE REPORT:
Report from referee #1:
Comment to Response 1: I disagree with the authors' response, as using the expression "strain-like" in the title clearly aims to compare the observed phenomena with prion strains.
Comment to Response 2: OK.
